ABCC1 and non-small cell lung carcinoma: This system effectively delivered anticancer drugs (doxorubicin and cisplatin) and two types of siRNA targeted to multidrug resistance-associated protein 1 (MRP1) and Bcl-2 mRNA for suppression of the pump and non-pump cellular resistance in non-small cell lung carcinoma, respectively.